Clinical studies on trastuzumab deruxtecan for human epidermal growth factor receptor 2-positive brain metastases Several previous clinical studies have suggested significant intracranial activity of trastuzumab derux...Clinical studies on trastuzumab deruxtecan for human epidermal growth factor receptor 2-positive brain metastases Several previous clinical studies have suggested significant intracranial activity of trastuzumab deruxtecan(T-DXd)in brain metastases(BMs)of human epidermal growth factor receptor 2(HER2)-positive(HER2-positive)metastatic breast cancer(mBC).Pooled analyses from DESTINY-Breast(DB)01,02,and 03 showed that T-DXd outperformed controls in terms of intracranial overall response rate(ORR)and median progression-free survival(mPFS).展开更多
The diagnosis of cancer‐related microangiopathic hemolytic anemia(CR‐MAHA)in patients with breast cancer is often delayed,and this condition is associated with high mortality.A 71‐year‐old female with CR‐MAHA sec...The diagnosis of cancer‐related microangiopathic hemolytic anemia(CR‐MAHA)in patients with breast cancer is often delayed,and this condition is associated with high mortality.A 71‐year‐old female with CR‐MAHA secondary to bone marrow metastasis received trastuzumab deruxtecan(T‐DXd)after first‐line chemotherapy failure and achieved partial hematological remission.Treatment was discontinued because of interstitial lung disease(ILD).Early antitumor therapy is crucial;antibody‐drug conjugates such as T‐DXd offer promise,but vigilance for adverse effects is needed.展开更多
目的对德曲妥珠单抗(trastuzumab deruxtecan,T-DXd)相关不良事件数据进行挖掘,为其临床管理及不良事件处理提供参考。方法基于美国食品药品监督管理局不良事件报告系统(Food and Drug Administration Adverse Event Reporting System,F...目的对德曲妥珠单抗(trastuzumab deruxtecan,T-DXd)相关不良事件数据进行挖掘,为其临床管理及不良事件处理提供参考。方法基于美国食品药品监督管理局不良事件报告系统(Food and Drug Administration Adverse Event Reporting System,FAERS)数据库,提取T-DXd上市后至2024年第4季度呈报的数据,通过比例失衡法中报告比值比(reporting odds ratio,ROR)法对T-DXd相关不良事件数据进行挖掘与分析。结果通过FAERS数据库共获得T-DXd相关不良事件13134例次。胃肠系统疾病占比最多,共2348个不良反应信号,占比17.88%。发生频次较高的不良反应为恶心(n=809)、间质性肺疾病(n=732)、疲劳(n=579),ROR值最高的为李斯特菌胃肠炎(ROR=1228.74)。死亡病例数较高的为间质性肺疾病(226例)、肺部炎症(90例)、恶心(67例)。结论通过挖掘T-DXd真实世界相关不良事件的数据,提示治疗期间应密切监测肺功能、心功能、血常规等,对相应并发症早诊断、早治疗。展开更多
基金supported by the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences(No.2023-JKCS-23)the Special Research Fund for Central Universities,Peking Union Medical College(No.2022-I2M-C&T-A-014).
文摘Clinical studies on trastuzumab deruxtecan for human epidermal growth factor receptor 2-positive brain metastases Several previous clinical studies have suggested significant intracranial activity of trastuzumab deruxtecan(T-DXd)in brain metastases(BMs)of human epidermal growth factor receptor 2(HER2)-positive(HER2-positive)metastatic breast cancer(mBC).Pooled analyses from DESTINY-Breast(DB)01,02,and 03 showed that T-DXd outperformed controls in terms of intracranial overall response rate(ORR)and median progression-free survival(mPFS).
文摘The diagnosis of cancer‐related microangiopathic hemolytic anemia(CR‐MAHA)in patients with breast cancer is often delayed,and this condition is associated with high mortality.A 71‐year‐old female with CR‐MAHA secondary to bone marrow metastasis received trastuzumab deruxtecan(T‐DXd)after first‐line chemotherapy failure and achieved partial hematological remission.Treatment was discontinued because of interstitial lung disease(ILD).Early antitumor therapy is crucial;antibody‐drug conjugates such as T‐DXd offer promise,but vigilance for adverse effects is needed.
